Prittle Prattle Pr

Category: Health

  • Over 1,500 Join HCG Cancer Care’s Sarcoma Strong 5K Walkathon in Bengaluru to Raise Awareness on Rare Cancer

    Led by Manisha Kumar and Dr. Pramod Chinder, the walkathon highlighted early detection of sarcoma and brought together survivors, caregivers, oncologists, and community groups across Karnataka

     More than 1,500 participants gathered in Bengaluru for the Sarcoma Strong 5K Walkathon, organised by HCG Cancer Care, to raise awareness about sarcoma, one of the rarest and most aggressive forms of cancer. The event united survivors, caregivers, doctors, and supporters in a show of solidarity and commitment to early detection and better outcomes.
    The walkathon was flagged off by Manisha Kumar, Regional Business Head, HCG Cancer Care, and Dr. Pramod Chinder, Senior Consultant Orthopedic Oncologist, who reminded the public that sarcoma, despite accounting for just one percent of cancers, carries high risks if not detected early. Both emphasised the need for awareness in communities, as delayed diagnosis continues to be a major barrier in India.

    Participants included oncologists, physiotherapists, patient support groups, and schoolchildren, turning the morning into a platform for both education and inspiration. Survivors and their families shared stories of resilience, underscoring the importance of early intervention and the role of specialised cancer centres in treatment.

    The event also connected with the global Sarcoma Strong movement, ensuring that voices from India were part of an international awareness drive that runs across multiple countries in August. HCG Cancer Care announced that it would continue to support sarcoma research and extend community outreach programs across Karnataka in partnership with local NGOs.

    For many in attendance, the walkathon was more than an awareness event, it was a celebration of strength, survival, and the possibility of better futures through timely medical care.
    At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTube.

  • Mrs. Tina Ambani Inaugurates RoboGynIndia 2025 at Kokilaben Dhirubhai Ambani Hospital

    The 4th annual conference of the Association of Gynecological Robotic Surgeons convenes in Mumbai, spotlighting the convergence of surgical robotics and women’s health innovation

    Mrs. Tina Ambani, Chairperson of Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute, inaugurated RoboGynIndia 2025, the 4th Annual Conference of the Association of Gynecological Robotic Surgeons, held at the hospital in Mumbai.
    Delivering her remarks at the event, Mrs. Ambani said, “Robotics has proven to be a gamechanger in the field of gynaecology. And the confluence of future-ready technology and medical expertise is yielding incredible breakthroughs. That’s why conferences like RoboGynIndia are so important.”

    Mrs. Sonali Bendre Behl, present as Guest of Honour, reflected on her personal journey with cancer and her connection with Kokilaben Hospital. “Kokilaben hospital gave me a second life, and I’m forever grateful. The care and confidence they provide extends beyond the patient, it touches the entire family. I’m inspired to see how technology and compassion come together here to transform lives.”

    The conference also welcomed Dr. Santosh Shetty, CEO and Executive Director of Kokilaben Dhirubhai Ambani Hospital, as Special Invitee.
    RoboGynIndia 2025 brought together professionals committed to advancing gynecological care through robotic-assisted technologies. The platform was hosted at Kokilaben Hospital, which has consistently positioned itself as a center for advanced medical procedures and integrated care delivery.

    At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTube.

  • Mankind Pharma Reports ₹3,570 Cr Revenue in Q1FY26, Grows 24.5% YoY with 23.8% EBITDA Margin

    India’s fourth-largest pharma company posts strong domestic growth, 81.1% export surge, and 15% rise in consumer healthcare revenue led by flagship brands and new launches

     Mankind Pharma Limited (BSE: 543904 | NSE: MANKIND), India’s fourth-largest pharmaceutical company by revenue, has reported consolidated revenue of ₹3,570 crore for the quarter ended June 30, 2025, marking a year-on-year growth of 24.5 percent. The company’s EBITDA stood at ₹850 crore, translating into a margin of 23.8 percent, an improvement of 20 basis points over the same quarter last year.
    Mankind’s strong performance this quarter was led by its domestic formulation business, which contributed ₹3,101 crore in revenue, up 18.9 percent year-on-year. Its export segment also delivered a significant boost, growing by 81.1 percent to ₹469 crore, driven primarily by the consolidation of BSV and incremental gains in its base business.
    The company’s consumer healthcare vertical reported ₹237 crore in revenue, representing a 15 percent increase compared to the corresponding quarter last year. This growth was supported by robust performance from its leading over-the-counter brands such as Gas-O-Fast, Manforce Condoms, HealthOk, and Preganews, which registered secondary sales growth of 36%, 18%, 15%, and 12% respectively.

    Within the domestic pharmaceutical business, Mankind continued to outperform the Indian Pharmaceutical Market (IPM). Secondary sales grew by 9.2 percent versus the IPM’s 8.6 percent, with respiratory and anti-infective therapies delivering 17.8 percent and 9.1 percent growth, respectively. Chronic therapies also contributed to the outperformance, with cardiac and anti-diabetic portfolios expanding at 1.5x and 1.6x the IPM growth rate.
    The company’s market share rose to 4.9 percent as of June 2025, up from 4.8 percent in March, consolidating its leadership in physician prescriptions. Mankind has maintained the number one position in India by prescription share for eight consecutive years, currently holding a 15.4 percent share, as per IQVIA June 2025 data.

    Notably, the company also reported expansion in its e-commerce and modern trade (MT) channels. These accounted for 11 percent of consumer healthcare revenue in Q1FY26, compared to 9 percent in the same period last year, supported by approximately 50 percent YoY growth in digital and organised retail distribution.
    On the product innovation front, Mankind Pharma continues to scale its consumer health portfolio with new launches such as Epic ThinX (premium unflavored condoms), Nimulid in pain management, and OvaNews (ovulation detection kit), positioning itself to capture growth across lifestyle and wellness categories.
    Mankind’s financial data reflects both volume and portfolio expansion. Gross margins for the quarter stood at 70.5 percent, and PAT margin was 12.5 percent. Profit after tax came in at ₹445 crore, while diluted earnings per share (EPS) stood at ₹10.6.

    The company’s Q1FY26 performance was also notable in the context of sequential momentum. Compared to Q4FY25, revenue rose 15.9 percent, while EBITDA was up 24 percent. This suggests operating leverage coming into play, with continued margin discipline and revenue scale.
    The earnings call for Q1FY26 is scheduled on 1st August 2025 at 12:00 PM IST. Investors can access the call through the company’s designated universal access numbers or via Diamond Pass registration.
    As Mankind Pharma continues to deepen its footprint across therapeutic and consumer categories, its balanced growth across prescription-led, OTC, and global markets underscores its dual focus on domestic leadership and international scale.

    At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTube.

  • SMT Limited Moves Toward IPO With ₹1,024.88 Cr in FY25 Revenue and CE-Backed Innovations

    Founded by Dhirajlal Kotadia, the medical device firm leads India’s DES market and expands across 76 countries with patented tech and strategic acquisitions

    Sahajanand Medical Technologies Limited (SMT), a company anchored in precision-driven cardiovascular care, has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) to initiate its public listing on the BSE and NSE. The IPO is structured entirely as an offer for sale, comprising up to 27,644,231 equity shares of face value ₹1 each, offered by its promoters and institutional investors.
    Founded in 2001 by Dhirajlal Kotadia, SMT has steadily scaled its reputation in the Class III and Class C/D medical devices space, developing proprietary solutions in both vascular and structural heart intervention. As of March 31, 2025, the company has commercial presence in 76 countries and operates through a mix of direct subsidiaries and distributor-led models, particularly in Europe, Southeast Asia, and Latin America.

    The offer for sale includes equity shares from major stakeholders including Shree Hari Trust, Dhirajkumar Savjibhai Vasoya, Samara Capital Markets Holding Limited, Kotak Pre-IPO Opportunities Fund, and NHPEA Sparkle Holding B.V. Other notable shareholders include Plutus Wealth Management LLP and individual investor Ashish Kacholia.
    The IPO structure reserves a discount-linked subscription for eligible employees under the employee reservation portion, while the broader allocation follows the book-building format: not more than 50% to qualified institutional buyers (QIBs), a minimum of 15% to non-institutional investors, and at least 35% to retail investors.
    SMT’s product lineup spans coronary stents, coronary balloons, renal stents, trans-catheter aortic valves, occluders, and peripheral drug-coated balloons. Its flagship innovation, Supraflex Cruz, is a drug-eluting stent (DES) built with a biodegradable polymer and enhanced deliverability through SMT’s proprietary LDZ link. SMT is also credited as the first company globally to secure a CE certification for a biodegradable polymer DES.

    According to data from the F&S Report included in the DRHP, SMT holds a 25% market share in India’s DES segment as of CY2025, leading by volume. It is also ranked among the top five DES suppliers by volume in Germany, Spain, Poland, and Brazil. The company has also secured top-five placement in the occluders segment in India, Thailand, and South Korea.
    SMT has two R&D centers, one in India and another in Thailand, supporting a portfolio of 102 granted patents and 71 active patent applications worldwide, along with five design registrations in India. Following its acquisition of Thailand-based Vascular Innovations, SMT developed the Aortic Valve Delivery Catheter (AVDC) system for its Hydra TAVI product, further expanding its innovation capabilities.
    On the financial front, SMT reported revenue from operations of ₹1,024.88 crore in Fiscal 2025, a 13.67% increase from ₹901.60 crore in Fiscal 2024. This growth was attributed largely to strong device sales across Europe and the rest of the world, with particular momentum in the structural heart vertical. The company also posted a profit of ₹25.15 crore in FY25, a reversal from a loss of ₹7.35 crore in the previous fiscal year.

    Domestically, SMT operates through a hybrid distribution model, supplying devices to hospitals including Narayana Hrudayalaya Limited. In Europe, the company runs direct operations in Germany, Spain, France, and the United Kingdom. It has transitioned from distributor-led to direct models in Spain, following the acquisition of Imex, and now operates a hybrid model in Brazil through its acquisition of Zarek.
    SMT’s clinical credibility is reinforced by 72 clinical studies, of which 60 have been completed and 12 are ongoing. These trials span diverse geographies and patient populations, focusing on core offerings such as Supraflex Cruz, Hydra, Pipit, and Cocoon.

    The IPO is being managed by Motilal Oswal Investment Advisors Limited, Avendus Capital Private Limited, HSBC Securities and Capital Markets (India) Private Limited, and Nuvama Wealth Management Limited. MUFG Intime India Private Limited is acting as the registrar to the issue.
    SMT’s public issue positions the company to consolidate its leadership in the cardiovascular device space, deepen its reach across regulated international markets, and maintain its focus on research-led manufacturing. With India now crossing 50% non-fossil installed power capacity and medical infrastructure seeing increased capital flow, SMT’s timing aligns with broader themes of precision healthcare, regulatory maturity, and Make in India–backed innovation.
    At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTube.

  • Shark Tank India Season 5 Sets Up Audition Booth at Indian Healthy Snacking Summit 2025

    1,500 founders and brands expected at Farmley’s Bharat Mandapam summit as live pitches go to Shark Tank panel

    Farmley has partnered with Shark Tank India to offer entrepreneurs direct access to Season 5 auditions at the Indian Healthy Snacking Summit 2025. The summit, scheduled for Friday at Bharat Mandapam, will feature an on-site Shark Tank booth where founders can record their pitches live. These recordings will be forwarded to the show’s production team in Mumbai for evaluation and potential selection for the upcoming season.
    The recorded pitches will serve as official auditions for Shark Tank India Season 5. Selected founders could go on to present their ideas in front of the show’s panel of investors, gaining national exposure and potential funding. This is the first time Shark Tank India is enabling on-ground auditions outside its traditional online process.

    Akash Sharma, Co-founder of Farmley, commented, “Every successful entrepreneur’s journey begins with a single opportunity to be heard. This on-ground audition format is revolutionizing how we discover and nurture talent, giving founders the chance to showcase their vision in a more personal, accessible setting. It’s not just about pitching – it’s about empowering the next generation of business leaders.”
    The Indian Healthy Snacking Summit 2025, now in its second edition, is expected to host over 1,500 attendees and feature more than 50 speakers. The summit has emerged as a strategic gathering point for emerging D2C brands, investors, food-tech players, and quick commerce platforms.
    Among the keynote speakers and panelists are Revant Himatsingka aka FoodPharmer, Amitesh Jha, CEO of Swiggy Instamart, and Arjun Vaidya, founder of Dr. Vaidya’s and V3 Ventures. The speaker lineup also includes senior leadership from Amazon, Blinkit, Zepto, and Meesho. Panel discussions will dive into evolving investment trends, digital distribution strategies, and India’s rising demand for healthier food products.

    For Farmley, this summit is more than just a branding platform. It marks a broader positioning shift as the company takes on a leadership role within the D2C health snacking space. By facilitating direct access to Shark Tank auditions, Farmley is reinforcing its commitment to supporting early-stage businesses and founder innovation.
    Farmley, founded in 2017 and headquartered in Noida, operates on a farm-to-palm model, sourcing directly from over 5,000 farmers across India. The company produces healthy snacks such as makhanas, dry fruits, and superfood-based mixes at its in-house facilities. With a national footprint and a robust D2C strategy, Farmley is endorsed by Rahul Dravid and has become a recognizable name in India’s wellness-oriented FMCG segment.

    In May 2025, Farmley raised $42 million in a Series C funding round led by L Catterton and DSG Consumer Partners. The capital is being used to expand distribution channels, invest in food innovation, and strengthen the company’s omnichannel presence across Tier 1 and Tier 2 cities.
    The Shark Tank booth at the Indian Healthy Snacking Summit represents a unique touchpoint where India’s next-generation founders can access the national stage. As Shark Tank India prepares to launch its fifth season, this on-ground scouting initiative is a sign of how startup discovery is becoming increasingly democratized.
    At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTube.

  • Travel Food Services IPO receives strong interest with 2.88x subscription; institutional bids lead demand

    Travel Food Services Limited receives 2.88 times total subscription as institutional demand outpaces expectations; company looks to deepen travel F\&B dominance with post-listing growth roadmap

    Travel Food Services Limited concluded its initial public offering with a total subscription of 2.88 times, backed by significant participation from institutional investors. The IPO, priced in the range of ₹1,045 to ₹1,100 per share, attracted total bids for 3,86,35,012 shares, compared to the offer size of 1,34,12,842 shares.

     Institutional capital dominates
    Qualified Institutional Buyers accounted for the largest portion of the demand, applying for 2,93,98,278 shares against 38,20,095 shares reserved. This translates to a subscription of 7.70 times for the QIB category, reflecting strong confidence from global and domestic financial institutions.
    The non-institutional investor category, which includes high-net-worth individuals and corporates, subscribed 1.27 times. Bidders in this segment applied under amounts above two lakh rupees, indicating steady interest from private capital sources.
    Retail Individual Investors showed a moderate response with a subscription of 0.69 times. The employee reserved segment, however, was fully subscribed at 1.72 times, signaling internal alignment with the company’s growth prospects.

     Lead managers and registrar
    The offering was managed by four lead managers:

    • Kotak Mahindra Capital Company Limited
    • HSBC Securities and Capital Markets (India) Private Limited
    • ICICI Securities Limited
    • Batlivala and Karani Securities India Private Limited
    • The registrar to the issue is MUFG Intime India Private Limited.

    Company profile
    Travel Food Services operates food and beverage outlets as well as lounge services at domestic and international travel hubs. As of March 2025, the company maintains a presence in 14 major Indian airports, alongside operations in Malaysia and Hong Kong.
    The company serves travellers through a curated portfolio of 127 food and beverage brands, combining in-house concepts with partner brands. Its lounges cater to passengers eligible through airline partnerships, card memberships, and loyalty programmes.
    It also runs quick service restaurants across nine highways in India, expanding its access to on-road travellers. The company has established itself as a key player in both the airport food and lounge categories.

     Performance snapshot
    According to its latest financial disclosures, Travel Food Services reported revenue of ₹1,687.74 crore for the year ended March 2025. This marks an increase of 20.87 percent over the previous fiscal year. Net profit for the same period reached ₹379.66 crore, growing 27.35 percent year-on-year.
    With its IPO now closed and investor interest recorded across categories, the company prepares to build on its presence in India’s travel and hospitality space.
    At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTube.

  • Huawei Watch Fit 4 Series Launches in India with Real-Time Sport Tracking and Emotional Wellbeing Assistant

    Huawei’s newest smartwatch lineup brings holistic health, intelligent navigation, and lifestyle elegance to fitness-first users across the country.

     Huawei has officially launched the next generation of its fitness-oriented smartwatch lineup in India with the debut of the HUAWEI WATCH FIT 4 and HUAWEI WATCH FIT 4 Pro. Designed for users who balance health goals with productivity and aesthetics, the new wearables combine cutting-edge health tracking, enhanced battery performance, and versatile design options across Android and iOS platforms.

    Both variants feature a large 1.82-inch AMOLED display with advanced metrics including real-time heart rate monitoring, SpO₂, sleep analysis, menstrual insights, and Huawei’s AI-powered stress tracking. The devices support over 100 workout modes, quick reply messaging, Bluetooth calling, voice note functions, and an Emotional Wellbeing Assistant integrated with Huawei Health+.

    Precision, Durability, and Smart Design
    The WATCH FIT 4 Pro stands out with a titanium alloy bezel, aluminum alloy case, and rotating crown navigation. With 3000-nit brightness, IP6X dust resistance, and diving support up to 40 metres, the Pro edition is engineered for outdoor and underwater sports with dual-band GNSS (L1 + L5) and 5ATM water resistance.
    Available in Green Nylon, Blue Fluoroelastomer, and Black Fluoroelastomer straps, it also supports wireless charging and boasts up to 10 days of battery life.

    Meanwhile, the WATCH FIT 4 targets everyday users with a lightweight 27g profile and 9.5mm thickness. Its bezel-less HD display, square aesthetic, and color choices in Black, White, Purple, and Gray make it ideal for urban wearers seeking all-day comfort. The user interface and health tracking metrics are easily accessible, delivering a seamless smartwatch experience that feels intuitive whether you’re navigating fitness insights or checking notifications. Beyond the look and feel, the Fit 4 also integrates deeply with Huawei’s ecosystem, syncing with Huawei Health+ to provide long-term wellness guidance and daily activity optimization without technical clutter. This balance of aesthetic precision and technical performance ensures the Fit 4 offers more than style, it delivers a complete, day-long smart assistant on the wrist.
    At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTube.

  • LT Foods Crosses USD 1 Billion Revenue Mark in FY’25, Reports 12 Percent Growth Year-on-Year

    LT Foods crosses the USD 1 billion mark in FY’25 with robust growth across premium Basmati rice, organic foods, and ready-to-cook segments, underpinned by global distribution, product innovation, and digital transformation.

    LT Foods Limited, a global player in the specialty rice and consumer food segment, has posted its consolidated audited financial results for the fiscal year ending 31 March 2025. The company recorded a total revenue of ₹8,770 crore, marking a 12 percent increase over the previous fiscal. The performance is driven by robust growth in its flagship basmati rice brand DAAWAT®, its expanding portfolio in organic ingredients, and the Ready-to-Heat and Ready-to-Cook segments.

    The company’s gross profit rose to ₹3,030 crore in FY’25, reflecting a year-on-year increase of 19 percent. Gross margin expanded by 200 basis points to 34.5 percent. EBITDA stood at ₹1,067 crore, an 8 percent rise over FY’24, while net profit increased marginally to ₹612 crore. The earnings per share (EPS) improved slightly to ₹17.43 from ₹17.09 in the previous fiscal.
    According to Mr. Ashwani Arora, Managing Director and Chief Executive Officer of LT Foods, the revenue milestone reflects consumer trust, innovation, and operational discipline across global markets. He stated that the company’s investments in its brand ecosystem, marketing, and distribution capabilities were instrumental in sustaining growth momentum. LT Foods’ India business saw continued investment in digital transformation and distribution strengthening, including the roll-out of its new go-to-market platform. Channels such as e-commerce and modern trade have contributed significantly to the company’s domestic footprint.

    The company’s international operations were key contributors. LT Foods distributes in over 80 countries and maintains a global footprint with supply chain hubs and manufacturing facilities in India, the United States, and Europe. Its North American rice brand Royal® continues to be a market leader, while its organic food division expanded by 29 percent in FY’25, reflecting rising demand for health-forward options.
    Product innovation has been another pillar of growth. LT Foods launched several new items under its health and gourmet categories. These include DAAWAT® Jasmine Thai Rice and a gluten-free snack range under the brand Kari Kari, including the newly introduced Krispy Hopu with a sweet and salty flavour profile. The RTH and RTC portfolio, including variants such as Quick Cooking Black Rice, Red Rice, and Cuppa Rice, contributed ₹188 crore in revenue and saw 21 percent growth.

    The company’s performance is further underlined by financial stability. LT Foods maintained an interest coverage ratio of 10.0 and a net debt-to-equity ratio of 0.16 for FY’25. Its return on capital employed stood at 21 percent, and return on equity was recorded at 16.8 percent. Cash profit for the year reached ₹797 crore, up 6 percent from the previous year.
    LT Foods, listed on the National Stock Exchange and BSE India, operates under an integrated farm-to-fork model. The company sources, processes, and distributes a portfolio of rice, organic food, and ingredients with certifications such as Kosher and Halal. The brand continues to align with sustainability goals, digital transformation, and responsible sourcing as part of its future strategy.DAAWAT®, its flagship brand, has remained one of India’s top-selling basmati labels. According to data from Wikipedia on Basmati rice, India accounts for more than 70 percent of global basmati exports, positioning LT Foods strategically in the global rice economy. The company’s focus on quality, traceability, and premiumization continues to drive its leadership in both the domestic and international food sectors.
    At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTube.

  • Sigachi Industries Expands MCC Dominance and Launches API Manufacturing Facility in Andhra Pradesh

    India’s top excipient player scales new verticals with the launch of a 25-acre API and specialty chemical site while maintaining its global MCC leadership.

    Sigachi Industries Ltd., India’s largest manufacturer of Microcrystalline Cellulose (MCC), has announced the next phase of its expansion with the establishment of a bulk drugs and specialty chemicals facility in Orvakal, Andhra Pradesh. This vertically integrated move signals the company’s diversification into regulated Active Pharmaceutical Ingredients (APIs) and strengthens its capacity to serve global pharma and nutraceutical clients.
    Sigachi has received Terms of Reference (ToR) approval from SEIAA, Andhra Pradesh, and will initiate its Environment Clearance (EC) process from July 15, 2025. Development is scheduled to begin on August 1, 2025.

    New API Facility: Sigachi Orvakal Node
    The new site spans over 25 acres in the Guttapadu-Orvakal industrial corridor. It is designed to offer high-volume manufacturing with flexible regulatory alignment for both regulated and semi-regulated markets. The facility is positioned to enhance Sigachi’s R&D responsiveness, speed up commercialisation timelines, and cater to new therapeutic segments.
    According to Mr. Amit Raj Sinha, Managing Director and CEO, “FY25 has been a transformative year. With Orvakal, we add depth to our infrastructure and scale to our ambition. This facility gives us room to serve new therapeutic spaces and increase our responsiveness to global demand.”

    MCC: Sigachi’s Flagship Segment
    Sigachi continues to lead the global excipient space with over 22,000 MTPA of MCC capacity, operating at over 80 percent utilisation. The company has developed more than 60 MCC grades under proprietary formulations, including its DAPOBAL process and acid recovery systems. MCC remains a key ingredient in oral solid dosage forms, and Sigachi’s offerings are widely used by both generics and innovators worldwide.
    Its facilities hold certifications from USFDA, EDQM, EXCiPACT, ISO 9001, ISO 14001, and ISO 45001.

    Financial Highlights
    In FY25, Sigachi reported revenue of ₹5,003 million, reflecting 25.4 percent growth, with EBITDA up 46.2 percent. The company has maintained strong operating margins and low debt, with 28 percent PAT CAGR over five years.
    Innovation and Pipeline
    Sigachi operates two DSIR-certified R&D centers in Hyderabad and Dahej. Its current roadmap includes:
    • Introduction of Croscarmellose Sodium (CCS)
    • Expansion of co-processed MCC variants
    • Entry into 3D-printed pharmaceutical applications
    • Launch of an API-focused R&D and analytics hub by FY26
    The company is also expanding into LATAM, ASEAN, and Middle East markets. Operations and maintenance (O&M) contracts now contribute 10 percent of group revenue. Over 98 percent of vendors meet ESG benchmarks.
    At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTube.